Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05514496 · ClinicalTrials.gov registry record · Phase 1
A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer
A Phase 1 study of EGFR Mutation-Related Tumors, sponsored by Nalo Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 258
- Enrollment target
- 12
- Study locations
NCT05514496: Active Phase 1 study of EGFR Mutation-Related Tumors, sponsored by Nalo Therapeutics.
NCT05514496 is a Phase 1 study of EGFR Mutation-Related Tumors that is active but no longer recruiting, run by Nalo Therapeutics. The registered enrollment target is 258 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (330% higher). The trial reports 12 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05514496, a Phase 1 study of EGFR Mutation-Related Tumors, is active but no longer recruiting, sponsored by Nalo Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 258 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of NX-019 and preliminary efficacy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutant cancer.
Conditions Studied
Interventions
- DRUG NX-019
Study Locations (12)
Other
- Seoul National University Hospital - Seoul
- Severance Hospital - Seoul
- Asan Medical Center - Seoul
- Samsung Medical Center - Seoul
California
- City of Hope Comprehensive Cancer Center - Duarte - Duarte
- City of Hope - Seacliff - Huntington Beach
- City of Hope Orange County Lennar Foundation Cancer Center - Irvine
Minnesota
- HealthPartners Frauenshuh Cancer Center - Saint Louis Park
- HealthPartners Cancer Center at Regions Hospital - Saint Paul
Virginia
- University Of Virginia Comprehensive Cancer Center - Charlottesville
- NEXT Virginia - Fairfax
Taipei
- National Taiwan University Cancer Center - Taipei City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2022-10-05 |
| Est. Completion | 2025-12-01 |
| Phase | Phase 1 |
What the registry record for NCT05514496 still lists
NCT05514496 is an interventional study that assigns participants to a tested intervention. The registered 258 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (330% higher).
The record links to 1 condition, with EGFR Mutation-Related Tumors appearing as the primary indexed condition, and to 1 intervention - of which NX-019 is the first listed.
NCT05514496 lists 12 locations in 5 states (Other, California, Minnesota).
Frequently Asked Questions
What is clinical trial NCT05514496 about?
NCT05514496 is a clinical study titled "A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer". This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of NX-019 and preliminary efficacy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutant cancer.
What is the current status of trial NCT05514496?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 258 participants. The study started on 2022-10-05. Estimated completion is 2025-12-01.
What conditions does trial NCT05514496 study?
This clinical trial studies the following conditions: EGFR Mutation-Related Tumors.
What interventions are being tested in trial NCT05514496?
The interventions under investigation include: NX-019 (DRUG).
Who is sponsoring clinical trial NCT05514496?
This trial is sponsored by Nalo Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05514496 being conducted?
This trial has 12 study locations across California, Minnesota, Virginia, Taipei. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for EGFR Mutation-Related Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05514496's enrollment target sits among peer trials
258 167th of 2000 higher than 1,833 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03785288 · 258 participants · Phase 3
Vaginal Cuff Brachytherapy Fractionation Study
- NCT04643002 · 258 participants · Phase 1
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
- NCT04924322 · 258 participants · Phase 2
Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies
- NCT05043012 · 258 participants · NA
Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI